Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety

Aboelnaga Engy M
El-beshbishi Wafaa

Open link

Publication date

August 2021

DOI

10.2478/fco-2019-0015

Publisher

Walter de Gruyter GmbH

Journal

Forum of Clinical Oncology

Abstract

A lower dose of capecitabine revealed better toxicity profiles and comparable efficacy in treatment of metastatic breast cancer (MBC). We aimed to evaluate the efficacy and toxicity of lower dose of capecitabine in comparison with the standard dose

Extracted data

We use cookies to provide a better user experience.

Data Protection

Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety

Abstract

Extracted data

Comparative study of low dose of capecitabine versus standard dose in metastatic breast cancer: Efficacy and safety

Abstract

Extracted data

Related items

Related items